Purpose: Preoperative C-reactive protein is a strong predictor of recurrence and prognosis in patients with renal cell carcinoma while postoperative C-reactive protein reportedly predicts survival in patients with metastatic renal cell carcinoma. We evaluated the impact of postoperative C-reactive protein on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. Materials and Methods: We defined increased preoperative C-reactive protein as 1 mg/dl or greater and postoperative C-reactive protein normalization as at least 1 postoperative measurement of less than 0.3 mg/dl. We reviewed the records of 263 patients with N0M0 clear cell renal cell carcinoma who underwent nephrectomy, and in whom preoperative and postoperative C-reactive protein values were available. We used multivariate analysis to identify independent factors predicting recurrence and prognosis. We also evaluated C-reactive protein at recurrence and its impact on survival. Results: Increased preoperative C-reactive protein and nonnormalization of postoperative C-reactive protein were associated with worse clinicopathological factors. Postoperative C-reactive protein nonnormalization, increased preoperative C-reactive protein, microvascular invasion and histological tumor necrosis were independent predictors for recurrence. Risk stratification using these factors effectively predicted the possibility of recurrence. Anemia, thrombocytosis and postoperative C-reactive protein nonnormalization were independent predictors of overall survival. Postoperative followup revealed recurrence in 50 patients. The 3-year survival rate in patients with C-reactive protein 0.3 mg/dl or greater at recurrence was significantly lower than that in patients with less than 0.3 mg/dl at recurrence (47.3% vs 81.6%). Conclusions: Nonnormalization of postoperative C-reactive protein is a strong predictor of recurrence and prognosis. Patients with C-reactive protein 0.3 mg/dl or greater at recurrence might not survive as long as those with C-reactive protein less than 0.3 mg/dl at recurrence.
机构:
Ben Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, IsraelBen Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, Israel
Kedar, I
;
Mermershtain, W
论文数: 0引用数: 0
h-index: 0
机构:
Ben Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, IsraelBen Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, Israel
Mermershtain, W
;
Ivgi, H
论文数: 0引用数: 0
h-index: 0
机构:
Ben Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, IsraelBen Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, Israel
机构:
Ben Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, IsraelBen Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, Israel
Kedar, I
;
Mermershtain, W
论文数: 0引用数: 0
h-index: 0
机构:
Ben Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, IsraelBen Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, Israel
Mermershtain, W
;
Ivgi, H
论文数: 0引用数: 0
h-index: 0
机构:
Ben Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, IsraelBen Gurion Univ Negev, Med Ctr, Inst Oncol, Fac Hlth Sci,Biotherapy Unit,Soroka, Beer Sheva, Israel